Researchers in Japan, led by the University of Tokyo, are set to begin human clinical trials in April 2026 for a promising vaccine against the deadly Nipah virus, which has a fatality rate of up to 75%.
A team of researchers in Japan has announced a clinical trial to confirm a vaccine’s efficacy against the deadly Nipah virus in humans.
The vaccine candidate developed at the University of Tokyo is set to start clinical trials in Belgium in April, Nikkei Asia, a Japan-based English-language news magazine, reported. The new vaccine offers a potential breakthrough against a disease whose fatality rate is estimated to be between 40 per cent and 75 per cent.
Currently, there is no licensed vaccine or specific treatment for Nipah virus infection.
The latest development comes even as India reported two confirmed cases of Nipah virus from West Bengal in January.The new vaccine is reportedly being developed by inserting a portion of the Nipah virus’s genetic information into the measles virus.
